15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion

15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion

[!NOTE] Guideline Recommendation: The ACC/AHA Secondary Prevention Guidelines and the USPHS Guidelines mandate that all tobacco-dependent patients undergoing cardiac rehabilitation be offered first-line pharmacotherapy unless medically contraindicated. Pharmacotherapy addresses the neurochemical dependence on nicotine, reducing craving intensity and withdrawal symptoms so patients can effectively engage in behavioral modification.

Nicotine dependence is driven by the neurobiological stimulation of alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptors in the ventral tegmental area (VTA) of the brain. Binding triggers rapid dopamine release in the nucleus accumbens, creating the classic neurochemical reward pathway. With chronic smoking, receptors upregulate and desensitize; abrupt cessation causes dopamine depletion, precipitating severe affective and somatic withdrawal symptoms. Pharmacologic therapies double to triple long-term cessation success, transforming 1-year unassisted quit rates of 3% to 5% into sustained abstinence rates of 25% to 35%.

---

First-Line Pharmacotherapy Options

The FDA has approved seven first-line pharmacotherapies: five formulations of Nicotine Replacement Therapy (NRT), Varenicline, and Bupropion SR.

1. Nicotine Replacement Therapy (NRT)

NRT provides controlled, medicinal nicotine delivery without the toxic carbon monoxide, oxidant gases, carcinogens, or tar particulates present in combustible tobacco smoke. By preventing abrupt plasma nicotine troughs, NRT attenuates withdrawal cravings.

Transdermal Nicotine Patch (Long-Acting)

• Pharmacokinetics: Continuous, slow transdermal absorption reaching steady-state plasma concentrations over 4 to 9 hours. Provides flat, consistent baseline blood levels over 16 to 24 hours.
• Standard Step-Down Dosing Schedules:
  • Heavy Smokers (>10 cigarettes/day or >half pack):
    • Step 1 (21 mg/day) for 4 to 6 weeks.
    • Step 2 (14 mg/day) for 2 weeks.
    • Step 3 (7 mg/day) for 2 weeks.
  • Light Smokers (≤10 cigarettes/day):
    • Initiate therapy at Step 2 (14 mg/day) for 6 weeks, then step down to Step 3 (7 mg/day) for 2 to 4 weeks.
• Application Instructions & Adverse Effects: Apply once daily in the morning to clean, dry, hairless skin on the upper body or outer arm; rotate sites daily to prevent contact dermatitis. If the patient experiences sleep disturbances or vivid dreams, advise removing the patch at bedtime (using a 16-hour wear schedule) or stepping down the patch strength.

Short-Acting NRT Formulations (Rescue Dosing)

• Nicotine Gum & Lozenge:
  • Dose Stratification by Time to First Cigarette (TTFC):
    • If the patient smokes their first cigarette within 30 minutes of waking: Prescribe the 4 mg dose (indicates high physiological dependence).
    • If the patient smokes more than 30 minutes after waking: Prescribe the 2 mg dose.
  • Chew-and-Park Technique for Gum: Chew slowly until a distinct peppery taste or tingling sensation appears (approximately 15–30 chews), then "park" the gum between the buccal mucosa and gum tissue to allow passive transmucosal absorption. When the tingle fades (after 1–2 minutes), chew again and park in a different location. Repeat over 30 minutes. Swallowing nicotine-rich saliva rapidly causes nausea, hiccups, dyspepsia, and throat irritation.
  • Acidic Beverage Restriction: Patients must avoid acidic beverages (such as coffee, carbonated sodas, citrus juices, wine, or energy drinks) for 15 minutes before and during the use of gum or lozenges, as an acidic oral pH prevents non-ionized nicotine absorption across the buccal mucosa.
• Nicotine Oral Inhaler: Delivers nicotine vapor via buccal absorption upon puffing. Provides oral tactile stimulation that satisfies hand-to-mouth behavioral rituals. Recommended: 6 to 16 cartridges daily.
• Nicotine Nasal Spray: Rapid mucosal absorption providing the fastest arterial nicotine rise among NRTs (venous-like peak within 5–10 minutes). Higher risk of nasal irritation and dependency; requires frequent dosing.

Combination NRT (Clinical Gold Standard)

Clinical practice guidelines strongly endorse combination NRT—pairing a long-acting transdermal patch (which supplies consistent baseline steady-state nicotine) with a short-acting agent (gum, lozenge, or inhaler taken prn for acute, breakthrough cravings). Multiple randomized meta-analyses confirm that combination NRT achieves significantly higher 6-month and 1-year abstinence rates than any single NRT monotherapy (odds ratio ~1.35 compared to patch alone).

Cardiovascular Safety of NRT

Historically, clinicians feared that NRT might trigger acute coronary events through hemodynamic stimulation. However, decades of clinical trials have proven that NRT is safe in patients with stable cardiovascular disease. Unlike cigarette smoke, NRT does not deliver carbon monoxide, does not cause carboxyhemoglobinemia, does not deliver oxidant free radicals, and produces blunted, gradual plasma nicotine curves without the sharp arterial spikes that trigger sudden catecholamine surges. While caution was traditionally advised in patients with unstable angina or within 2 weeks of acute MI, modern consensus panels endorse supervised NRT use in stabilized post-ACS patients when the alternative is continued combustible smoking.

---

2. Varenicline Tartrate (Chantix)

Mechanism of Action

Varenicline is a synthetic small molecule that functions as a highly selective partial agonist at α4β2 neuronal nicotinic acetylcholine receptors:

• Partial Agonist (Agonist Effect): Binds to the receptor and stimulates moderate dopamine release (~40% to 60% of the maximum dopamine surge elicited by nicotine). This maintains baseline mesolimbic dopamine tone, effectively suppressing cravings and withdrawal symptoms.
• Competitive Antagonist (Antagonist Effect): Binds with exceptionally high affinity, occupying the receptor and competitively preventing nicotine from inhaled tobacco smoke from binding. If a patient lapses and smokes a cigarette, they experience no neurochemical reward or satisfaction, extinguishing the reinforcing behavior.

Clinical Dosing Titration

To minimize gastrointestinal adverse effects, varenicline requires a 1-week upward dose titration prior to the target quit date:

• Days 1 to 3: 0.5 mg orally once daily in the morning.
• Days 4 to 7: 0.5 mg orally twice daily (morning and evening).
• Day 8 through Week 12: 1.0 mg orally twice daily.
• Treatment Duration: Standard course is 12 weeks. In patients who achieve complete abstinence at 12 weeks, an additional 12 weeks of maintenance therapy (24 weeks total) is recommended to prevent late relapse.

Landmark Clinical Trials & Cardiovascular Safety

• EVITA Trial (Evaluation of Varenicline in Smoking Cessation After Acute Coronary Syndrome): A landmark randomized, double-blind, placebo-controlled trial enrolling 302 patients across 24 hospitals. Varenicline was initiated in-hospital during admission for acute coronary syndrome (ACS). At 24 weeks, continuous smoking abstinence was 35.8% in the varenicline group versus 25.8% in the placebo group (p < 0.05). Importantly, rates of Major Adverse Cardiovascular Events (MACE: cardiovascular death, recurrent MI, stroke, stent thrombosis) were identical between groups, verifying the safety of acute varenicline initiation in ACS.
• CATS Trial (Cessation After Troponin S): Further evaluated post-ACS cohorts, demonstrating robust efficacy without any signal of increased ventricular arrhythmias, recurrent ischemic hospitalization, or hemodynamic instability.
• EAGLES Trial: Evaluated 8,144 smokers across 16 countries, comparing varenicline, bupropion, nicotine patch, and placebo in patients with and without psychiatric illness. EAGLES definitively demonstrated no increase in neuropsychiatric adverse events (leading the FDA to remove the boxed warning in 2016) and confirmed equivalent cardiovascular safety across all active treatment arms.
• Common Adverse Effects: Nausea occurs in approximately 30% of patients. Clinicians should instruct patients to take varenicline with a full meal and a large glass of water. Other common side effects include abnormal/vivid dreams and insomnia.

---

3. Bupropion Hydrochloride Sustained-Release (Zyban / Wellbutrin SR)

Mechanism of Action

Bupropion SR is a monocyclic aminoketone antidepressant that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and a non-competitive antagonist at nicotinic acetylcholine receptors. By inhibiting the neuronal reuptake of dopamine and norepinephrine in the central nervous system, bupropion mimics nicotine's neurochemical effects, mitigating withdrawal and reducing craving frequency.

Dosing Titration

Therapy begins 1 to 2 weeks before the target quit date to achieve steady-state therapeutic plasma concentrations:

• Days 1 to 3: 150 mg orally once daily in the morning.
• Day 4 through Week 7–12: 150 mg orally twice daily (doses must be separated by at least 8 hours to minimize seizure risk; the second dose should be taken in late afternoon rather than bedtime to prevent insomnia).

Clinical Profile & Weight Gain Mitigation

• Weight Gain Delay: Bupropion is uniquely beneficial for patients concerned about post-cessation weight gain, as it significantly delays weight accumulation during active therapy.
• Comorbid Depression: Highly favorable for patients with coexisting depressive symptoms or seasonal affective disorder.

Absolute Contraindications and Warnings

• Seizure Disorders: Bupropion lowers the seizure threshold in a dose-dependent manner (seizure incidence ~0.1% at 300 mg/day). It is strictly contraindicated in patients with active epilepsy or any history of seizures.
• Eating Disorders: Contraindicated in patients with a current or prior diagnosis of anorexia nervosa or bulimia, due to an increased risk of seizures.
• Abrupt Substance Withdrawal: Contraindicated during abrupt withdrawal from alcohol, benzodiazepines, or other sedatives.
• MAO Inhibitors: Must not be used concurrently with or within 14 days of discontinuing monoamine oxidase inhibitors.
• Blood Pressure Monitoring: Bupropion can induce mild-to-moderate elevations in resting blood pressure; monitor resting blood pressure regularly during cardiac rehabilitation.

---

Comparison of First-Line Tobacco Cessation Pharmacotherapies

---

Realistic Clinical Scenario: Pharmacotherapy Selection in Post-ACS Patient

Clinical Scenario: A 56-year-old male is enrolled in Phase II cardiac rehabilitation 3 weeks after an acute anterior STEMI treated with a drug-eluting stent to the LAD. He smoked 25 cigarettes per day for 30 years and smoked his first cigarette within 5 minutes of waking. He has mild hypertension (BP 132/84 mmHg on carvedilol and ramipril) and no history of seizures, psychiatric illness, or renal disease. He is highly motivated to quit but reports extreme anxiety and failed cold-turkey attempts in the past.

Clinical Decision-Making:

• Nicotine Dependence: TTFC <30 minutes confirms severe physical dependence.
• Evidence-Based Selection: The CCRP nurse and medical director discuss first-line options. Given his recent STEMI, the team reviews the EVITA trial, which confirmed that varenicline initiated post-ACS is safe, does not increase cardiovascular adverse events, and offers superior long-term abstinence compared to placebo.
• Prescription & Education: Varenicline is initiated with standard titration: 0.5 mg daily for 3 days, 0.5 mg twice daily for 4 days, then 1.0 mg twice daily for 12 weeks. The patient is instructed to take doses after meals with a full glass of water to avoid nausea. Because of high breakthrough anxiety, he is also provided with short-acting 4 mg nicotine lozenges to carry during exercise sessions for acute distress.